Center for Molecular Medicine to Offer Three AviaraDx Cancer Tests | GenomeWeb
NEW YORK (GenomeWeb News) - The Center for Molecular Medicine said today that it will offer three cancer tests developed by AviaraDx in an effort to help physicians make more informed decisions in managing oncology patients.
 
Under the agreement, CMM said it will advise physicians on the value and clinical utility of the AviaraDx tests, and will coordinate sample preparation and shipping. AviaraDx will analyze the tumor samples in its CLIA-certified, CAP-accredited laboratory.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.